Table 2.
Clinical and pathologic characteristics of the chemoradiotherapy responder and chemoradiotherapy non-responder groups.
| Characteristic | Chemoradiotherapy responder group (n = 85) | Chemoradiotherapy non-responder group (n = 90) | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % | Mean | SD | No. | % | Mean | SD | ||
| Sex: | 0.404 | ||||||||
| Male | 58 | 68.2 | 56 | 62.2 | |||||
| Female | 27 | 31.8 | 34 | 37.8 | |||||
| Age | 55.47 | 11.5 | 54.97 | 12.7 | 0.782 | ||||
| T stage*: | 0.204 | ||||||||
| T2 | 3 | 3.5 | 2 | 2.2 | |||||
| T3 | 48 | 56.5 | 40 | 44.4 | |||||
| T4b | 34 | 40 | 48 | 53.3 | |||||
| N stage*: | 0.459 | ||||||||
| N negative | 25 | 29.4 | 22 | 24.4 | |||||
| N positive | 60 | 70.6 | 68 | 75.6 | |||||
| LN number | 6.75 | 4.6 | 8.38 | 5.9 | |||||
| LN Metastasis | 0.008 | ||||||||
| Yes | 79 | 92.9 | 71 | 78.9 | |||||
| None | 6 | 7.1 | 19 | 21.1 | |||||
| PNI | 0.014 | ||||||||
| Yes | 85 | 100 | 83 | 92.2 | |||||
| None | 0 | 0 | 7 | 7.8 | |||||
| TD | 0.084 | ||||||||
| Yes | 84 | 98.8 | 83 | 92.2 | |||||
| None | 1 | 1.2 | 7 | 7.8 | |||||
| LVI | 0.143 | ||||||||
| Yes | 84 | 98.8 | 84 | 93.3 | |||||
| None | 1 | 1.2 | 6 | 6.7 | |||||
| Pathology types of ADC | 0.773 | ||||||||
| Highly differentiated | 0 | 0 | 2 | 2.2 | |||||
| Middle differentiated | 74 | 87.1 | 74 | 82.2 | |||||
| Poorly differentiated | 7 | 8.2 | 8 | 8.9 | |||||
| Undifferentiated | 4 | 4.7 | 6 | 6.7 | |||||
| Survival status: | 0.331 | ||||||||
| Alive | 76 | 76.5 | 76 | 72.2 | |||||
| Dead | 9 | 23.5 | 14 | 27.8 | |||||
| CEA | 10.8 | 26.4 | 16.4 | 31.1 | 0.208 | ||||
| Ca 19-9 | 22.5 | 33.3 | 43.7 | 111.2 | 0.093 | ||||
| Neoadjuvant chemotherapy regimen | 0.508 | ||||||||
| None | 0 | 0 | 2 | 2.2 | |||||
| Capecitabine | 12 | 14.1 | 18 | 20 | |||||
| CAPOX | 72 | 84.7 | 65 | 72.2 | |||||
| FOLFOX | 1 | 1.2 | 4 | 4.4 | |||||
| 5-FU | 0 | 0 | 1 | 1.1 | |||||
| Neoadjuvant chemotherapy cycles: | 0.014 | ||||||||
| 0 | 0 | 0 | 2 | 2.3 | |||||
| 1 | 0 | 0 | 1 | 1.1 | |||||
| 2 | 33 | 38.8 | 54 | 60 | |||||
| 3 | 22 | 25.9 | 12 | 13.3 | |||||
| 4 | 30 | 35.3 | 21 | 23.3 | |||||
| Adjuvant chemotherapy regimen | 0.387 | ||||||||
| None | 14 | 16.5 | 15 | 16.7 | |||||
| Capecitabine | 8 | 9.4 | 12 | 13.3 | |||||
| CAPOX | 62 | 72.9 | 58 | 64.4 | |||||
| FOLFOX | 1 | 1.2 | 4 | 4.4 | |||||
| 5-FU | 0 | 0 | 1 | 1.2 | |||||
| Adjuvant chemotherapy cycles: | 0.310 | ||||||||
| 0 | 14 | 16.5 | 15 | 16.7 | |||||
| 1 | 7 | 8.3 | 7 | 7.8 | |||||
| 2 | 17 | 20 | 7 | 7.8 | |||||
| 3 | 11 | 12.9 | 12 | 13.3 | |||||
| 4 | 19 | 22.3 | 20 | 22.2 | |||||
| 5 | 5 | 5.9 | 5 | 5.6 | |||||
| 6 | 11 | 12.9 | 21 | 23.3 | |||||
| 8 | 1 | 1.2 | 3 | 3.3 | |||||
| Surgical procedure: | 0.235 | ||||||||
| AR | 55 | 64.7 | 63 | 70 | |||||
| APR | 29 | 34.1 | 23 | 25.6 | |||||
| Hartmann | 1 | 1.2 | 4 | 4.4 | |||||
| Pim-3 expression | 0.001 | ||||||||
| Negative | 33 | 38.8 | 12 | 13.4 | |||||
| Weak | 30 | 35.3 | 36 | 40 | |||||
| Moderate | 15 | 17.7 | 29 | 32.2 | |||||
| Strong | 7 | 8.2 | 13 | 14.4 | |||||
*The T and N stages were based on preoperative MRI. TRG, tumor regression grading; 5-FU, 5 fluorouracil; AR, anterior resection; APR, abdominal perineal resection; ADC: adenocarcinoma; LN: lymph node; PNI: perineural invasion; LVI: lymphovascular invasion.